October 16, 2015 News by Patricia Silva, PhD GATE Trial Supports Generic Glatiramer Acetate as an Alternative Therapy for Relapsing-Remitting Multiple Sclerosis The Glatiramer Acetate Clinical Trial to Assess Equivalence With CopaxoneĀ (GATE) seems to be the first phase 3 clinical trial to test a generic disease-modifying medication for multiple sclerosis (MS) treatment. The data showed that glatiramer acetate, the generic drug, was equivalent to the trademark drug Copaxone for the…
October 16, 2015 News by Patricia Silva, PhD Researchers Develop Potential Inhibitors for Proteins Involved in Cancer, Multiple Sclerosis and other Autoimmune Diseases A new study published in the Journal of Biological Chemistry revealed novel potential inhibitors of specific proteins involved in the pathogenesis of cancer and autoimmune disorders, like multiple sclerosis. The study is entitled āDual Targeting of the Chemokine Receptors CXCR4 and ACKR3 with Novel…
October 15, 2015 News by Patricia Silva, PhD EMD Serono Announces Publication of PRISMS-15 Years Follow-up Study Results on Rebif for RelapsingāRemitting Multiple Sclerosis EMD Serono, the U.S. biopharmaceutical division of Merck KGaA, Darmstadt, Germany, recently announced that the results of the 15 year follow-up trial PRISMS-15 (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) evaluating RebifĀ® (interferon beta-1a), a high-dose, high-frequency interferon beta for the treatment of…
October 15, 2015 News by Patricia Silva, PhD Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl) Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the companyās product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…
October 15, 2015 News by Maureen Newman The Future of Stem Cell Therapy for Multiple Sclerosis Patients Relies on Clinical Trial Participation Among the different therapeuticĀ approaches being explored for treating MS,Ā adult stem cell therapy continues to beĀ one of the most discussed and anticipatedĀ in the MS community. āStem cellsā ā the common term for undifferentiated, self-renewing proliferating cells āĀ are currently being investigated for their ability to treatĀ patients in a wide range of disease…
October 14, 2015 News by Margarida Azevedo, MSc Study Identifies Blood Coagulation Protein Fibrinogen as Cause of Brain Autoimmunity Researchers from the Gladstone Institutes have shown in a new study that fibrinogen, an important blood coagulation protein, can induce an autoimmune response in the central nervous system when the blood-brain barrier (BBB) is disrupted and blood proteins enter the brain. The study, entitled āBlood coagulation protein fibrinogen promotes…
October 14, 2015 News by admin Study Reports No Influence of Vitamin D Supplementation on Inflammation in Relapsing-Remitting Multiple Sclerosis A recentĀ study of people with relapsing remittingĀ multiple sclerosis (RRMS) found thatĀ high-dose oral vitamin D3 supplementation did not influence markers of inflammation. Inflammation is a reaction to bodily injury that may be over-activated in people with multiple sclerosis (MS).Ā The article, titled “Vitamin D supplementation and systemic inflammation in…
October 13, 2015 News by Patricia Silva, PhD Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015 A session titled āLate Breaking Newsā was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, 2015, in Barcelona, Spain. At this session, Prof. Xavier Montalban from the Hospital Vall d’Hebron University in Barcelona presented data on the promising Genentech/Roche…
October 13, 2015 News by Patricia Silva, PhD Importance of Microbiota in MS Development Explored in ECTRIMS 2015 Presentation Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 ā 10, 2015). The first parallel session was entitled āWill…
October 12, 2015 News by Patricia Silva, PhD Prof. Jorge Correale Reviews Environmental Factors Associated with Multiple Sclerosis at ECTRIMS 2015 Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 ā 10, 2015). The first parallel session was entitled āWill MS…
October 12, 2015 News by Patricia Silva, PhD Update on Alemtuzumab (Genzyme’s Lemtrada) Clinical Trial Data Presented at ECTRIMS 2015 Multiple Sclerosis News Today recently attended the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā held in Barcelona, Spain, October 7 to 10, 2015. On Friday, October 9, three parallel sessions entitled āFree Communicationsā took place. In the first session, several topics related to multiple…
October 10, 2015 News by Patricia Silva, PhD EXCLUSIVE: Genentech/Roche Interview with MS News Today on Promising MS Therapy Ocrelizumab #ECTRIMS 2015 Dr. Peter Chin, a renowned neurologist and Principal Medical Director of Global Neuroscience Development at Genentech, a leading biotechnology company and member of the Roche Group, participated in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros on the companyās promising multiple sclerosis (MS) therapy…
October 10, 2015 News by BioNews Staff Mike Nace, Editor-in-Chief of Multiple Sclerosis News Today, Reviews Day 2-3 at #ECTRIMS2015 https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3 Read theĀ articles mentioned in theĀ podcast: #ECTRIMS2015 ā Another Attendee Record #ECTRIMS2015 ā āVitamin D plays important role in MS inflammation.ā ā Jorge Correale #ECTRIMS2015 ā āWhen you stop smoking you can decrease the risk of disease progression.ā ā Jorge Correale Discovering a New World in…
October 9, 2015 News by Patricia Silva, PhD Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis, ECTRIMS 2015 Genzyme, aĀ SanofiĀ company, recently announced novel positive 5-year experimental dataĀ from the extension study of LemtradaĀ®Ā (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS). The findings were presented today, October 9, at the 31stĀ Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. LemtradaĀ®Ā (alemtuzumab), developedĀ by Genzyme, is…
October 9, 2015 News by Margarida Azevedo, MSc Promising Data on ZINBRYTA (Daclizumab High-Yield Process) Compared to Interferon Beta-1a in RRMS, ECTRIMS 2015 Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the compound ZINBRYTA TM at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain. The full results of the 2 to 3-year long…
October 9, 2015 News by Patricia Silva, PhD Biometrica MS Launched at ECTRIMS 2015 to Support Routine Multiple Sclerosis Care Biometrica MS, a technology that provides an easy to use service for neurologists to quantify lesion load as well as brain volume measures in clinical practice, is a web-based image analysis tool that was recently launched at the 31st Congress of the European Committee for Treatment and Research in Multiple…
October 9, 2015 News by Malika Ammam, PhD Gilenya’s Clinical Trial Results Presented at ECTRIMS Reinforce Long-Term Efficacy Profile in RMS Patients On October 8, 2015, data on two Phase III clinical trials called FREEDOMS and FREEDOMS II on Gilenya (fingolimod), a drug developed byĀ Novartis, were presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain (October 7-10).
October 9, 2015 News by Patricia Silva, PhD EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today After Presenting New Data on Biogen’s TECFIDERA at #ECTRIMS2015 A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled āMS developments: transitioning evidence into clinical practiceā presentedĀ by the companyĀ this morning at the 31st Congress of the European Committee for Treatment and…
October 9, 2015 News by Patricia Silva, PhD New 3-Times-Per-Week Regimen For Teva’s Copaxone Safe, Effective & Increases Patient Compliance #ECTRIMS2015 A Satellite Symposia entitled āDiscovering a new world in MSā presentedĀ by Teva Neuroscience was held yesterday, October 8 at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā currently taking place in Barcelona, Spain, October 7 ā 10, 2015. Dr. Omar Khan from the…
October 9, 2015 News by Patricia Silva, PhD Potential MS Drug Cladribine Reported To Have No Impact on Cancer Incidence A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…
October 9, 2015 News by Patricia Silva, PhD Discovering a New World in MS Through Genomics, ECTRIMS 2015 A Satellite Symposia entitled āDiscovering a new world in MSā supported by Teva Neuroscience was held yesterday, October 8, at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently taking place in Barcelona, Spain, October 7 ā 10, 2015. Prof. David Brassat…
October 9, 2015 News by Patricia Inacio, PhD Ocrelizumab: Could Genentech/Rocheās Experimental Drug Be the First Effective Progressive MS Therapy? Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent…
October 9, 2015 News by Marta Ribeiro #ECTRIMS2015 – “Overall fat intake not significantly associated with MS risk.” – Kjetil L. Bjornevik “Overall fat intake not significantly associated with MS risk.” – Kjetil L. Bjornevik Dr. Kjetil BjĆørnevik is a professor ofĀ Neurology, Epidemiology atĀ University of Bergen. For full coverageĀ on social media forĀ #ECTRIMS2015Ā go toĀ https://bit.ly/ECTRIMS2015…
October 8, 2015 News by admin Does Sun Exposure in Early Years Delay MS Onset? Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D levelārelated factors,” appeared October 7, 2015 in the journal Neurology.
October 8, 2015 News by Patricia Inacio, PhD ECTRIMS Highlights Latest Developments in Multiple Sclerosis Research The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is currently being held in Barcelona, from 7 to 10 of October, 2015. As the biggest scientific event focused on Multiple Sclerosis, researchers and clinicians from around the world, with more than 8,000 participants, gather…
October 8, 2015 News by Patricia Silva, PhD MS Care: A Hot Topic at #ECTRIMS2015 Three āHot Topic Sessionsā on multiple sclerosis will take place this afternoon (17:00 ā 17:45 h, GMT + 1h) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain, October 7 ā 10. The first session is entitled…
October 8, 2015 News by Malika Ammam, PhD Biomarkers and Predictors For Developing Future Personalized MS Therapies Discussed at ECTRIMS 2015 New developments in the diagnosis and treatment of multiple sclerosis (MS) are being discussed at this year’sĀ 31st annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). TheĀ symposium, being held in Barcelona, Spain, will fosterĀ discussions about development of individualized therapiesĀ forĀ MS patients throughĀ a more targeted and efficient…
October 8, 2015 News by Patricia Silva, PhD Aubagio (Teriflunomide) Slows Brain Atrophy in Patients with Relapsing Multiple Sclerosis GenzymeĀ recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that AubagioĀ®Ā (teriflunomide) was able to slow the loss of brain volume (or atrophy) versus a placebo over two years in patients with relapsing multiple sclerosis (RMS). Brain volume loss (BVL)…
October 8, 2015 News by Patricia Silva, PhD Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015 Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatmentĀ forĀ relapsing-remitting multiple sclerosis (RRMS), during theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) happening now in Barcelona, Spain until October 10, 2015. The…
October 8, 2015 News by Patricia Silva, PhD Acorda To Present New Data on MS Therapies AMPYRA and Experimental rHIgM22 at #ECTRIMS2015 Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRAĀ® (dalfampridine) Extended Release Tablets (10 mg) Ā at this year’sĀ 31st Congress of the European Committee for Treatment and Research in…